Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) traded up 4.8% during trading on Tuesday . The company traded as high as $12.13 and last traded at $12.04. 31,787 shares changed hands during trading, a decline of 87% from the average session volume of 244,637 shares. The stock had previously closed at $11.49.
Analyst Upgrades and Downgrades
MAZE has been the topic of a number of recent analyst reports. Leerink Partners initiated coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price target on the stock. Guggenheim started coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set a "buy" rating and a $19.00 target price on the stock. Leerink Partnrs upgraded Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. JPMorgan Chase & Co. started coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued an "overweight" rating and a $30.00 price objective for the company. Finally, TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $25.67.
View Our Latest Stock Report on MAZE
Maze Therapeutics Trading Down 6.9 %
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Further Reading
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
